Morgan Stanley Keeps Their Hold Rating on SanBio Co (SNBIF)
In a report released on May 29, Shinichiro Muraoka from Morgan Stanley maintained a Hold rating on SanBio Co (SNBIF – Research Report), with a price target of Yen1,400.00.
Confident Investing Starts Here:
Muraoka covers the Healthcare sector, focusing on stocks such as SanBio Co, Astellas Pharma, and Daiichi Sankyo Company. According to TipRanks, Muraoka has an average return of -3.9% and a 33.33% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Sell analyst consensus rating for SanBio Co with a $5.83 average price target.
Based on SanBio Co's latest earnings release for the quarter ending January 31, the company reported a quarterly GAAP net loss of $730.52 million. In comparison, last year the company had a GAAP net loss of $761.28 million
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 hours ago
- Business Insider
Kymera Therapeutics upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley upgraded Kymera Therapeutics (KYMR) to Overweight from Equal Weight with a price target of $79, up from $49. The company reported Phase 1 data for STAT6 degraded KT-621 thtat the firm believes addressed key questions on safety and target knockdown, the analyst tells investors in a research note. The firm added that the data increases its confidence in KT-621's ability to compete across large immunology and inflammation indications and in Kymera's platform more broadly. Confident Investing Starts Here:
Yahoo
4 hours ago
- Yahoo
Monzo profit soars as British challenger bank boosts lending
The British lender now has more than 12 million customers, a rise of 2.4 million during the year, while deposits grew 48% to GBP16.6 billion. Monzo Bank said its profit quadrupled last year with a burgeoning loan book lifting revenue, as the mobile bank works toward an eventual stock market debut. The British lender posted a pretax profit of GBP60.4 million ($105.22 million) for the year through March compared to GBP15.4 million profit in the 13 months prior, with revenue jumping to GBP1.2 billion from GBP880 million. The 10-year-old firm lent GBP1.9 billion to its customers — a rise of 36% from a year ago. 'We've grown from a startup challenging the status quo, to a household name, a leading brand and the UK's 7th largest bank by customer numbers,' Chief Executive Officer TS Anil said in a statement. He added that Monzo now has more than 12 million customers, a rise of 2.4 million during the year, while deposits grew 48% to GBP16.6 billion. A third of customers are using Monzo as their primary bank, and the company has launched individual savings accounts to encourage customers to bring in even more of their money. Monzo is working with Morgan Stanley to arrange meetings with potential investors for an initial public offering that could take place as early as the first half of next year, Sky News reported last month. Anil told Bloomberg TV that Monzo 'will make a good public company one day', yet it was too early to talk about the details of any IPO plans. A listing could value Monzo at more than GBP6 billion, according to Sky. The firm's customers are mostly in the UK. For years, Monzo has been looking to expand in the US, and last year hired Conor Walsh, a former executive at Block's Cash App, to lead its business in the US. The firm also opened a Dublin office last year, marking its official European expansion. Last year, Monzo allowed employees to offload some of their stock in a secondary share sale that valued the company at US$5.9 billion. The bank booked a GBP53.4 million one-time cost linked to the share sale in its latest accounts. Investors in this round included Alphabet's independent growth fund Capital G, as well as new investors such as London-based venture capital firm Hedosophia. Chart: Bloomberg See Also: Click here to stay updated with the Latest Business & Investment News in Singapore MariBank launches invite-only access to global bonds via Pimco GIS Income Fund Trust Bank to launch TrustInvest in 2025 The digital banks that make a profit Read more stories about where the money flows, and analysis of the biggest market stories from Singapore and around the World Get in-depth insights from our expert contributors, and dive into financial and economic trends Follow the market issue situation with our daily updates Or want more Lifestyle and Passion stories? Click here
Business Insider
4 hours ago
- Business Insider
Merck held talks to buy MoonLake for over $3B, FT reports
Merck (MRK) held talks for a potential acquisition of Swiss biotechnology group MoonLake Immunotherapeutics (MLTX) valued at over $3B, Oliver Barnes and Patrick Temple-West of the Financial Times report, citing people familiar with the matter. An initial nonbinding offer from Merck was reportedly rejected by MoonLake, but discussions could be revived. Morgan Stanley and Goldman Sachs are advising MoonLake on the sale process. The U.S. pharmaceutical company is seeking to replenish its drug pipeline as its major cancer drug, Keytruda, approaches patent expiration. MoonLake, Merck, Goldman Sachs, and Morgan Stanley declined to comment. Confident Investing Starts Here:
